FDA allows use of Vertex’ Kalydeco in children aged under two
Use of Vertex Pharmaceuticals’ cystic fibrosis drug Kalydeco has been expanded in the US to include some children under the age of two.
Read More
Tag: CFTR
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
